Samumed to Release Phase II Results at AAD

An important bit of news has surfaced online this weekend about the heralded company Samumed.

Samumed will be presenting “Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial” on March 5th, 2016 at the 74th Annual Meeting of the American Academy of Dermatology. The entire conference will be held from March 4th-8th in Washington D.C. at the Walter E. Washington Convention Center. The thought of attending the conference is perhaps intriguing after learning about this presentation, however, if you want to make that happen tickets go for $2,220 for members of the public. Not to worry though, Samumed released the results from it’s last conference presentation (WCHR 2015) on their website a few days after the completion of that event.

The good news is March 5th is not too far away and the fact that Samumed wants to be on stage to present their Phase II results is a good thing. Typically companies do that when the proceedings will be in their favor. Samumed continues to move right along and we’re all holding out cups of gatorade for them.

4 thoughts on “Samumed to Release Phase II Results at AAD

  1. Thanks for the update! So eager to hear more about samumeds treatment. Let’s all hope that if it’s extremely effective that the cost of treatment won’t be too high. I’d say I’m being too optimistic but there trials have been running extremely smooth. Hopefully we could see this product out in early 2017

  2. Good morning, my name is Jose,

    I could say that results had this product in the fight with androgenic alopecia? do you have photos of pacients?

    when it could be the product for sale?

    Thanks you

    Jose Manuel

    • Hi Jose,

      The results will be presented on March 5. Maybe they will include photos. We don’t know when it will be on sale, maybe by the end of 2017.

Leave a Reply

Your email address will not be published. Required fields are marked *